Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 3/20 | 0.52 |
| ▸ | TP53 | P04637 | 3/20 | 0.52 |
| ▸ | MDM2 | Q00987 | 7/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3439705 | 1.00 | MDM4 (0.52) | MDM4TP53MDM2 | |
| SCHEMBL21474286 | 1.00 | MDM4 (0.52) | MDM4TP53MDM2 | |
| SCHEMBL29400729 | 1.00 | MDM4 (0.52) | MDM4TP53MDM2 | |
| SCHEMBL13697504 | 1.00 | MDM4 (0.52) | MDM4TP53MDM2 | |
| Cyclohexylamine SCHEMBL29401058 | 0.92 | MDM4 (0.48) | MDM4TP53MDM2 | |
| Cyclohexylamine SCHEMBL29401401 | 0.92 | MDM4 (0.48) | MDM4TP53MDM2 | |
| SCHEMBL29401227 | 0.92 | MDM4 (0.56) | MDM4TP53MDM2 | |
| SCHEMBL29368221 | 0.92 | MDM4 (0.56) | MDM4TP53MDM2 | |
| SCHEMBL1486207 | 0.92 | MDM4 (0.56) | MDM4TP53MDM2 | |
| SCHEMBL31382825 | 0.92 | MDM4 (0.46) | MDM4TP53MDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114349827-A | Synthetic method of brennuo peptide | 江苏诺泰澳赛诺生物制药股份有限公司 | 2022-04-15 | — | — | CN | claimed |
| CN-114315978-A | Method for synthesizing histrelin by solid-liquid method | 湖南三太药业有限公司 | 2022-04-12 | — | — | CN | claimed |
| CN-114276415-A | Method for synthesizing leuprorelin by solid-liquid method | 湖南三太药业有限公司 | 2022-04-05 | — | — | CN | claimed |
| CN-114230637-A | Method for synthesizing deslorelin by solid and liquid | 湖南三太药业有限公司 | 2022-03-25 | — | — | CN | claimed |
| CN-114181285-A | Method for synthesizing nafarelin by solid-liquid method | 湖南三太药业有限公司 | 2022-03-15 | — | — | CN | claimed |
| CN-110294800-B | Preparation method of somaglutide | 齐鲁制药有限公司 | 2022-03-04 | — | — | CN | claimed |
| CN-122075734-A | Conjugates comprising tetrapeptides, methods of making, intermediates and uses thereof | — | 2026-05-26 | — | — | CN | disclosed |
| US-12638394-B2 | Skin sensitization measuring reagent, method for measuring skin sensitization, and compound | FUJIFILM CORPORATION (JP) | 2026-05-26 | — | — | US | disclosed |
| EP-3916000-B1 | METHOD FOR PRODUCING PEPTIDE COMPOUND, PROTECTING GROUP-FORMING REAGENT, AND AROMATIC HETEROCYCLIC COMPOUND | FUJIFILM CORP (JP) | 2026-04-08 | — | — | EP | disclosed |
| US-20260077073-A1 | GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR)-TARGETED COMPOUNDS AND USES THEREOF | ALPHA 9 ONCOLOGY INC (CA) | 2026-03-19 | — | — | US | disclosed |
| EP-3774838-B9 | LIXISENATIDE SYNTHESIS WITH CAPPING | SANOFI AVENTIS DEUTSCHLAND (DE) | 2025-12-10 | — | — | EP | disclosed |
| EP-4655311-A1 | METHOD FOR SYNTHESIZING POLYPEPTIDES | Boehringer Ingelheim International GmbH (DE) | 2025-12-03 | — | — | EP | disclosed |
| US-20250361274-A1 | PEPTIDE AND PEPTIDE-CONTAINING AGENT | PEPTIDREAM INC. (JP) | 2025-11-27 | — | — | US | disclosed |
| CN-114230637-A | Method for synthesizing deslorelin by solid and liquid | 湖南三太药业有限公司 | 2022-03-25 | — | — | CN | disclosed |
| CN-114230653-A | Preparation method of chlorotoxin | 杭州禾泰健宇生物科技有限公司 | 2022-03-25 | — | — | CN | disclosed |
| CN-114181285-A | Method for synthesizing nafarelin by solid-liquid method | 湖南三太药业有限公司 | 2022-03-15 | — | — | CN | disclosed |
| WO-2022050529-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | ㈜베르티스 | 2022-03-10 | — | — | WO | disclosed |
| CN-110294800-B | Preparation method of somaglutide | 齐鲁制药有限公司 | 2022-03-04 | — | — | CN | disclosed |
| EP-3960753-A1 | SOLID PHASE PEPTIDE SYNTHESIS METHODS | Massachusetts Institute Of Technology (US) | 2022-03-02 | — | — | EP | disclosed |
| CN-114075274-A | Somarunotide analog and preparation method and application thereof | 浙江湃肽生物有限公司深圳分公司 | 2022-02-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12638394-B2 | Skin sensitization measuring reagent, method for measuring skin sensitization, and compound | HRH1, HRH4, CUTA | MDM4 3159/4885TP53 3805/4885MDM2 3842/4885 |
| US-20250361274-A1 | PEPTIDE AND PEPTIDE-CONTAINING AGENT | BMP4, BMP1, BMPR2 | MDM4 3599/4885TP53 3024/4885MDM2 4613/4885 |
| US-20260077073-A1 | GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR)-TARGETED COMPOUNDS AND USES THEREOF | GRPR, GIPR, GLP1R | MDM4 1761/4885TP53 630/4885MDM2 754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.